All In Biotech

Drug Trial Radar · NCT07337447

Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01)

PRODIGE 113 (FFCD 2314) - REWENEC 01 STUDY Randomized Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin. Phase II Comparative Randomized Study - Multicentric

Last checked: Nov 19, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 122 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

122

Planned (sponsor's estimate)

Start

Apr 2026

Primary completion

Apr 2029

Study completion Apr 2030

Sponsor

Lead sponsor
Hospices Civils de LyonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Federation Francophone de Cancerologie Digestive
First posted
Jan 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Background Neuroendocrine carcinomas (NECs) of gastro-entero-pancreatic (GEP) or unknown (UK) origin are rare and highly aggressive diseases. The recommended first-line (L1) treatment is platinum-etoposide combination therapy, which has a progression-free survival (PFS) of only 4-9 months and a median overall survival (OS) of approximately 12 months. All patients experience relapse, often rapidly after this first line of chemotherapy. The standard second-line (L2) chemotherapies recommended by ESMO, ENETS, and NCCN, FOLFIRI and FOLFOX, have modest efficacy with a PFS of 3 months and a median OS of 6 months. The BEVANEC study (PHRCK 2014, NCT02820857) reported no benefit of FOLFIRI + bevacizumab compared to FOLFIRI in a randomized phase II study that enrolled 150 patients in 26 centers over a period of 5 years in France. To date, the most promising efficacy data for this highly aggressive cancer come from clinical trials of immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 checkpoint. For example, in France, the non-comparative phase II NIPINEC trial (NCT03591731) randomized patients to receive nivolumab +/- ipilimumab in L2/3 and achieved its primary evaluation criterion (ORR-8 weeks\>10%). Other trials in Europe and worldwide have also reported efficacy data in the context of single-arm studies. Scientific Questions and Unmet Needs: 1. New therapeutic options/perspectives are necessary for patients with GEP/UK NECs given the limited overall survival. 2. Approximately 50% of patients experienced early progression under immunotherapy in the NIPINEC trial and other trials, which may be explained by the absence of chemotherapy combined with immunotherapy and/or the existence of resistance mechanisms. 3. In the GEP/UK NEC indication, the design of these immunotherapy trials has been non-comparative single-arm studies because the realization of randomized comparative trials is considered very difficult for these very rare cancers (incidence \<5/million). Rationale for the REWENEC-01 Trial The DURIGAST PRODIGE 59 study, conducted by the FFCD, demonstrated the feasibility and safety of the FOLFIRI + double immune checkpoint inhibitor (anti-PD-1 and anti-CTLA4) combination, as well as for the combination Folfox-Domvanalimab-Zimberelimab (anti-PD-1 and anti-TIGIT). In a translational study of the immune phenotype in patients with NECs treated with the anti-PD1 pembrolizumab, an increase in TIGIT expression was observed after pembrolizumab treatment and higher TIGIT expression on T cells in the blood of patients with high Ki67 expression in their tumors. These data suggest that TIGIT is a potential complementary therapeutic target to PD-1/PD-L1 checkpoint inhibition in GEP/UK NECs. Domvanalimab has been developed as an anti-TIGIT monoclonal antibody and zimberelimab as an anti-PD-1. Design and primary objective of the REWNEC-01 Trial The REWENEC-01 trial is a comparative phase II trial that will randomize GEP/UK NEC patients between an experimental arm FOLFIRI+Zimberelimab + Domvanalimab and a control arm FOLFIRI in L2. The FOLFIRI arm will be a "hybrid" synthetic control arm composed of patients from historical/external data from the FOLFIRI arm of BEVANEC and French retrospective studies RBNEC and CEPD, mixed with patients recruited prospectively during the trial and randomized to the control arm. The randomization ratio for patients included prospectively during the trial will be 4:1 (4 patients assigned to FOLFIRI+Zimberelimab + Domvanalimab for 1 patient assigned to FOLFIRI). The randomization algorithm will take into account "external" patients assigned progressively to the control arm to obtain a 1:1 ratio between the trial arms, with balanced distributions of stratification factors between the two arms. With 77 patients to be included, this strategy will provide statistical power equivalent to that of a trial including 122 patients, sufficient to demonstrate an advantage in overall survival rate at 12 months from 32% to 50%. The hypotheses related to efficacy criteria are formulated a priori, as recommended by the FDA guidance document on trials with synthetic/external control arms. The proof of concept has been reported at ESMO 2023. The primary judgment criterion will be the overall survival rate at 12 months because it is a strong and significant criterion for translating the clinical benefit of the Chemotherapy + Zimberelimab + Domvanalimab combination. The design with a hybrid synthetic control arm allows for the consideration of a randomized comparative study in a cancer as rare as neuroendocrine carcinoma.

Conditions

  • Carcinoma, Neuroendocrine

Interventions

  • FOLFIRI + Zimberelimab + DomvanalimabDrug

    FOLFIRI every 14 days + Zimberelimab IV every 28 days + Domvanalimab IV every 28 days

  • FOLFIRI (standard of care)Drug

    FOLFIRI every 14 days IV every 28 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival (%) between FOLFIRI and FOLFIRI+Zimberelimab+DomvanalimabTime frame: 6 months after the start of treatment 12 months after the start of treatment

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • CHU Amiens Picardie

    Amiens, France

  • CHU Avicenne APHP

    Bobigny, France

  • CHU Caen Normandie

    Caen, France

  • Hôpital Beaujon

    Clichy, France

  • Hôpital Henri MONDOR

    Créteil, France

  • CHU Dijon

    Dijon, France

  • CHU de Grenoble

    Grenoble, France

  • Centre Oscar Lambret

    Lille, France

  • Service d'Oncologie Médicale - Hôpital Edouard Herriot - Hospices Civils de Lyon

    Lyon, France

  • CHU Timone

    Marseille, France

  • Institut Paoli Calmettes

    Marseille, France

  • CHU Montpellier - Hôpital Saint Eloi

    Montpellier, France

  • HEGP

    Paris, France

  • Hôpital Saint Antoine APHP

    Paris, France

  • Hôpital Saint Louis APHP

    Paris, France

  • CHU de Bordeaux - Hôpital Haut-Leveque

    Pessac, France

  • CHU de Poitiers

    Poitiers, France

  • Hôpital Robert Debré, CHU de Reims

    Reims, France

  • CHU Rouen

    Rouen, France

  • Centre Paul Strauss

    Strasbourg, France

  • Institut Gustave Roussy

    Villejuif, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.